StockData
Bioventus Inc. logo

Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 2, 2026Score 13/3041% below fair value
$10.60+0.14 (+1.34%)

Close on Nov 17, 2026Market cap $891.37MP/E 13.8Yield –

Bioventus revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Bioventus's revenue for the twelve months ending Jun 27, 2026 was $581.85M, up 3.1% year over year. For fiscal 2025 it was $568.09M, down 0.9% from the year before. The highest annual figure on record is $573.28M in fiscal 2024.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$568.09M-0.9%
FY2024Dec 31, 2024$573.28M+11.9%
FY2023Dec 31, 2023$512.35M+0.0%
FY2022Dec 31, 2022$512.12M+18.8%
FY2021Dec 31, 2021$430.90M+34.2%
FY2020Dec 31, 2020$321.16M-5.6%
FY2019Dec 31, 2019$340.14M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$153.21M+3.8%
Q1 FY2026Mar 28, 2026$132.09M+6.6%
Q4 FY2025Dec 31, 2025$157.90M+2.8%
Q3 FY2025Sep 27, 2025$138.65M-0.2%
Q2 FY2025Jun 28, 2025$147.66M-2.4%
Q1 FY2025Mar 29, 2025$123.88M-4.3%
Q4 FY2024Dec 31, 2024$153.64M+13.5%
Q3 FY2024Sep 28, 2024$138.96M+15.0%
Q2 FY2024Jun 29, 2024$151.22M+10.3%
Q1 FY2024Mar 30, 2024$129.46M+8.7%
Q4 FY2023Dec 31, 2023$135.42M+7.6%
Q3 FY2023Sep 30, 2023$120.79M-6.1%
Q2 FY2023Jul 1, 2023$137.07M-2.3%
Q1 FY2023Apr 1, 2023$119.06M+1.5%
Q4 FY2022Dec 31, 2022$125.83M-3.5%
Q3 FY2022Oct 1, 2022$128.66M+18.2%
Q2 FY2022Jul 2, 2022$140.33M+27.8%
Q1 FY2022Apr 2, 2022$117.29M+43.4%
Q4 FY2021Dec 31, 2021$130.41M+32.3%
Q3 FY2021Oct 2, 2021$108.89M+26.8%
Q2 FY2021Jul 3, 2021$109.82M+89.3%
Q1 FY2021Apr 3, 2021$81.78M+4.0%
Q4 FY2020Dec 31, 2020$98.59M–
Q3 FY2020Sep 26, 2020$85.91M–
Q2 FY2020Jun 27, 2020$58.02M–
Q1 FY2020Mar 28, 2020$78.65M–

More Bioventus figures

See a number that looks wrong?